Adult Refsum Disease
A rare inherited peroxisomal disorder causing toxic buildup of phytanic acid, leading to progressive nerve, vision, and hearing problems that can often be managed with dietary treatment.
- Dietary management available
- Genetic testing confirmatory
- Specialist metabolic care
- Inheritance Pattern
- Autosomal Recessive
- Genes Involved
- PHYH, PEX7
- Typical Onset
- Childhood–Adulthood
- Key Management
- Dietary Phytanic Acid Restriction
Condition Overview
Adult Refsum Disease (ARD) is a rare inherited disorder of peroxisomal fatty acid metabolism caused by mutations in PHYH or, less commonly, PEX7. The defect prevents normal breakdown of phytanic acid, a fatty acid obtained from dietary sources such as dairy, ruminant fat, and certain fish, leading to its progressive accumulation in tissues.
Unlike many peroxisomal disorders that present in infancy, ARD typically becomes apparent later in childhood or adulthood, with a slowly progressive course affecting the peripheral nerves, retina, and inner ear.
Because phytanic acid accumulation is directly influenced by diet, ARD is one of the few genetic metabolic disorders where dietary modification can meaningfully slow disease progression, making early and accurate diagnosis particularly important.
Types and Subtypes
Adult Refsum Disease is generally considered a single clinical entity, though presentation and severity can vary based on the underlying gene and age of onset.
Symptoms and Signs
Symptoms typically develop slowly and can be subtle in early stages, often involving vision, hearing, and peripheral nerve function.
Causes and Risk Factors
ARD is caused by inherited enzyme deficiencies that impair phytanic acid breakdown; dietary intake of phytanic acid precursors influences disease severity but is not the underlying cause.
Diagnosis and Investigations
Diagnosis relies on biochemical confirmation of elevated phytanic acid together with genetic testing and assessment of affected organ systems.
Disease Severity Stratification
ARD is not staged like cancer; severity is generally classified by organ involvement and response to dietary management.
Standard Treatment Options
Management centers on reducing phytanic acid intake and supporting affected organ systems.
Advanced & Emerging Therapies
Most ARD management remains diet- and symptom-based; emerging approaches focus on optimizing acute and long-term phytanic acid reduction.
Procedural
Therapeutic plasmapheresis / lipid apheresis
Used during acute exacerbations or very high phytanic acid burden to rapidly lower levels.
Precision Medicine
Genotype-guided dietary counseling
Individualized dietary planning based on confirmed genetic diagnosis and biochemical response.
Investigational
Novel lipid-lowering and metabolic approaches
Research is ongoing into pharmacological strategies that might complement dietary management.
Biomarkers & Precision Medicine
Biochemical and genetic markers guide diagnosis and monitor treatment response over time.
When a Second Opinion May Be Important
Because ARD is rare and dietary management is highly individualized, specialist metabolic input can significantly improve outcomes.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis in ARD depends substantially on how early dietary treatment begins and how consistently it is maintained.
Supportive Care and Living With ARD
Ongoing multidisciplinary support helps individuals manage sensory, neurological, and dietary aspects of ARD.
How CancerFax Helps You Explore Treatment Options
CancerFax can help review your biochemical and genetic reports, coordinate a specialist second opinion, and connect you with metabolic dietitians and centers experienced in managing Adult Refsum Disease.
Get a free case reviewFrequently Asked Questions
Adult Refsum Disease is a rare inherited disorder caused by PHYH or PEX7 gene mutations that impair breakdown of phytanic acid, leading to its accumulation in the body.
Early signs often include night blindness, loss of smell, and mild peripheral neuropathy, which can develop gradually over years.
Yes. Because phytanic acid comes primarily from diet, restricting foods high in phytanate precursors can meaningfully lower circulating levels and slow disease progression.
Diagnosis combines elevated plasma phytanic acid levels with confirmatory PHYH or PEX7 genetic testing.
No. Both are peroxisomal disorders, but Zellweger syndrome is typically a severe infantile condition, while ARD usually presents later with a slower course.
A specialist dietitian typically recommends limiting dairy fat, ruminant meats, and certain fatty fish, which are high in phytanic acid precursors.
Yes, progressive hearing loss and retinitis pigmentosa causing night blindness and vision loss are common features.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene copy.
Care typically involves metabolic specialists, dietitians, ophthalmologists, audiologists, and neurologists.
Yes. CancerFax can help review medical and genetic reports, coordinate a second opinion, and connect you with metabolic specialists and dietitians experienced in managing Adult Refsum Disease.
Have an ARD Diagnosis or Lab Results to Review?
Share your reports with CancerFax to explore specialist second opinions and dietary management support.